Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients-Reference-Cited by-同舟云学术

Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients

Published:1997-06 Issue:6 Volume:36 Page:S116-S118
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Clucas Alan,Verschoore Michèle,Sorba Valérie,Poncet Michel,Baker Mike,Czernielewski Janusz

Publisher

Elsevier BV

Subject

Dermatology

Reference11 articles.

1. Adapalene, a new chemical entity with retinoid activity;Bernard;Skin Pharmacol,1993

2. The in vivo and in vitro anti-inflammatory activity of CD271, a new retinoid-like modulator of cell differentiation;Hensby,1989

3. Adapalene 0.1% gel has low skin irritation potential;Verschoore;J Am Acad Dermatol,1997

4. Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients;Caron;J Am Acad Dermatol,1997

5. Etude comparative de l'efficacité et de la tolérance de gels d'adapalène à 0.1 et 0.03% et d'un gel de trétinoïne à 0.025% dans le traitement de l'acné;Alirezaï;Ann Dermatol Venereol,1996

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of ceramides and niacinamide‐containing moisturizer versus hydrophilic cream in combination with topical anti‐acne treatment in mild to moderate acne vulgaris: A split face, double‐blinded, randomized controlled trial;Journal of Cosmetic Dermatology;2024-02

2. Efficacy and safety of microencapsulated benzoyl peroxide and microencapsulated tretinoin for the treatment of acne vulgaris: Results from two phase 3 double-blind, randomized, vehicle-controlled studies;Journal of the American Academy of Dermatology;2023-10

3. Adverse events related to topical drug treatments for acne vulgaris;Expert Opinion on Drug Safety;2020-04-02

4. Acne Vulgaris;Evidence-Based Dermatology;2014-06-06

5. Efficacy and safety of adapalene gel 0.1% and 0.3% and tretinoin gel 0.05% for acne vulgaris: results of a single-center, randomized, double-blinded, placebo-controlled clinical trial on Mexican patients (skin type III-IV);Journal of Cosmetic Dermatology;2013-06